Laboratory Management
Overview
Clinical genetic laboratories operate inside a layered regulatory framework (CLIA, CAP, FDA, state agencies, CLSI technical standards) that defines who may test, what may be tested, and how results must be reported. Every patient sample moves through three workflow phases - preanalytic (collection, transport, accessioning), analytic (extraction, assay, instrument run), and postanalytic (interpretation, reporting, sign-out) - and each phase has its own dominant error modes and controls.
Laboratory output is continuously monitored by paired quality assurance (system-level processes, training, document control, proficiency testing) and quality control (per-run measurements against expected values) programs, with documented validation before any test is offered clinically. Layered on top is a safety program covering biohazard containment, chemical hygiene, and waste streams. Most laboratory errors can be traced back to a specific phase or a specific control: identifying which phase and which control is the recurring diagnostic task.
Quality
Quality assurance and quality control are complementary. QA is the system: documented procedures, training records, proficiency testing enrollment, internal audits, and corrective and preventive action (CAPA). QC is the daily evidence: positive, negative, and no-template controls run with patient samples and judged against Westgard or equivalent rules. New assays are formally validated before clinical use, while modifications to validated FDA-cleared tests require verification of performance in the local lab.
Regulatory
CLIA is the federal floor for any US lab testing human specimens for diagnostic purposes and stratifies labs by test complexity (waived, moderate, high). Genetic testing is high-complexity and requires a qualified laboratory director. CAP accreditation is voluntary, deemed-status, and more rigorous than CLIA. The FDA distinguishes IVDs (manufactured kits) from LDTs (laboratory-developed tests); the long-standing enforcement-discretion posture for LDTs has shifted, with phased FDA oversight now in effect. New York CLEP imposes additional requirements for any lab reporting results on NY residents. CLSI publishes the consensus technical procedural standards that labs cite in SOPs.
Safety
Clinical specimens are handled at BSL-2 with universal precautions, an OSHA-compliant bloodborne pathogen exposure control plan, appropriate PPE, sharps and red-bag waste segregation, an accessible chemical hygiene plan, and current SDS access. BSL-3 and BSL-4 are reserved for specific high-risk pathogens and are not routine in clinical genetics labs.
Workflow Phases
The preanalytic phase is the largest source of laboratory error and includes ordering, patient identification, specimen collection, labeling, transport, and accessioning. The analytic phase covers extraction, the assay run itself, and the controls that judge whether the run is valid. The postanalytic phase covers variant interpretation, report generation, sign-out by a board-certified director, and turnaround time. Most reported errors (often cited as 60-70%) occur preanalytically, before the sample ever reaches the bench.